Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Inhibitors of Viral Protein Synthesis

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...

Hepatitis

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...

Viral Hepatitis I: Introduction

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...

Retrovirus Life Cycles

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...

Immune Response Against Viral Pathogens

Immune Response Against Viral Pathogens

The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Molecular Lubricant Mitigates Self-Assembled Monolayer Aggregation in Perovskite Photovoltaics.

Angewandte Chemie (International ed. in English)·2026

Same author

Self-Reported Dietary Attentiveness to Fruit and Vegetable Intake and Actigraphy-Measured Sleep Efficiency in Middle-Aged and Older Women: A Cross-Sectional Study.

Nutrients·2026

Same author

Pancreatic cancer fibrosis activates protumorigenic Schwann cells through a nuclear mechanosensing mechanism.

Gut·2026

Same author

Eutectic Urea Phosphate Suppresses Phase Segregation in Wide-Bandgap Photovoltaic Perovskites.

Angewandte Chemie (International ed. in English)·2026

Same author

Pancreatic cancer fibrosis activates protumorigenic Schwann cells through a nuclear mechanosensing mechanism.

bioRxiv : the preprint server for biology·2026

Same author

Enhancing prestin oligomerization for superior sonogenetics.

Theranostics·2026

Search research articles

Related Experiment Video

Updated: Jun 6, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

Evolution of interferon-based therapy for chronic hepatitis C.

Chun-Hao Chen¹, Ming-Lung Yu

¹Digestive Division, Department of Internal Medicine, Kaohsiung Municipal United Hospital, Kaohsiung 804, Taiwan.

Hepatitis Research and Treatment

|December 15, 2010

Summary

Interferon-based therapies for chronic hepatitis C have evolved, with pegylated interferon-alfa and ribavirin offering improved sustained virological response (SVR) rates, especially in certain genotypes.

More Related Videos

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons

Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons

Published on: August 23, 2016

Related Experiment Videos

Last Updated: Jun 6, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons

Zika Virus Infectious Cell Culture System and the In Vitro Prophylactic Effect of Interferons

Published on: August 23, 2016

Area of Science:

Hepatology
Virology
Pharmacology

Background:

Interferon-alfa (IFN-α) monotherapy for chronic hepatitis C (CHC) demonstrated low sustained response rates (8-9%).
Combination therapy with ribavirin significantly improved sustained virological response (SVR) rates, particularly for genotypes 2 or 3.
Pegylated interferon (PegIFN) further enhanced SVR rates, establishing PegIFN-α-ribavirin as the standard of care.

Purpose of the Study:

To review the evolution of interferon-based therapies for CHC.
To identify predictors of treatment efficacy for IFN-based regimens.
To discuss the impact of treatment response on SVR rates.

Main Methods:

Review of historical and current treatment guidelines and clinical trial data for CHC.
Analysis of factors influencing SVR rates in patients receiving IFN-based therapies.
Evaluation of virological response milestones (RVR, cEVR) as predictors of SVR.

Main Results:

PegIFN-α-ribavirin combination therapy offers optimal SVR rates, with treatment duration tailored to HCV genotype (48 weeks for HCV-1, 24 weeks for HCV-2/3).
Hepatitis C virus (HCV) genotype 2 or 3 infection is a strong baseline predictor of SVR.
Rapid virological response (RVR) is the most significant predictor of SVR; achieving a complete early virological response (cEVR) also correlates with high SVR rates (>90%).

Conclusions:

HCV genotype and early virological response are critical factors in predicting treatment success with PegIFN-ribavirin.
Patients with HCV-1 not achieving an early virological response (EVR) should consider discontinuing therapy.
Emerging protease inhibitors hold promise for novel triple combination therapies to further improve CHC treatment outcomes.